Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
⏸️ Investing
These 2 cryptocurrencies have smashed Bitcoin's returns in 2017
⏸️ Investing
Are these beaten down ASX shares in the buy zone?
⏸️ Investing
3 dirt cheap ASX shares I would avoid
⏸️ Investing
Broker names Mayne Pharma Group Ltd shares as a buy
⏸️ Investing
Mayne Pharma Group Ltd shares sink lower on AGM update
⏸️ Investing
5 shares you need to watch on Tuesday
⏸️ Investing
Are these 3 beaten down ASX shares bargain buys?
⏸️ Investing
Mayne Pharma Group Ltd shares slip to a 52-week low
⏸️ Investing
Is the Mayne Pharma Group Ltd share price heading lower?
⏸️ Investing
Why shares of Mayne Pharma Group Ltd are bouncing off 52-week lows
⏸️ Investing
Why these 4 ASX shares climbed higher today
⏸️ Investing
Why these 4 ASX shares are ending the week in the red
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
